Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #97

    Selv Oslo reagerede negativt.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #98

      Heldigvis lå genmab så højt, at der var noget "at tage af".

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #99

        🙂

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #100

          Genmab er oppe som nr 2 på c25 vinderlisten.

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #101

            Der var vist en efterregulering på europæisk PMI kl. 10. Den burde ikke kunne rykke markederne i noget særligt omfang.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #102

              Reguleringen var endda til den positive side.

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #103

                Lidt mystisk hvis det der det. Faldt til 52. Ventet 51,9

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bikube
                  wrote on sidst redigeret af
                  #104

                  Og $ flyver højt 7,21.

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    ProinvestorNEWS
                    wrote on sidst redigeret af
                    #105

                    Aktier/middag: C25 tynges af makrousikkerhed - SAS i tocifret fald https://www.proinvestor.com/investornyt/845961/aktier-middag-c25-tynges-af-makrousikkerhed-sas-i-tocifret-fald

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #106

                      Det ender med, at Helge må invitere på romkugler og Bjørnebryg i baghaven....

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #107

                        😄

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #108

                          Tror ikke der har været linket til denne:

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #109

                            Just a moment...

                            favicon

                            (firstwordpharma.com)

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #110

                              Johnson & Johnson's mAb looks set to win on all fronts over the next few years in the multiple myeloma market.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #111

                                Det bliver spændende:

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #112

                                  Data from Johnson & Johnson's Phase II LYNX study, which due to readout late this year or in early 2023, could provide some answers. This trial is evaluating Darzalex in combination with Kyprolis (carfilzomib) and dexamethasone (Kd), versus Kd alone, in approximately 230 patients that have received one to three prior lines of therapy, one of which contained Darzalex.

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #113

                                    Feedback from our poll overwhelmingly supports the assertion that MM patients can be re-treated with Darzalex, on the assumption that there has been an extended break in exposure to the drug. All 30 specialists said they are comfortable re-treating patients with Darzalex in these circumstances, with 50% of respondents describing themselves as 'very' comfortable with this approach and 37% as 'extremely' comfortable.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #114

                                      Ligeledes spændende:

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #115

                                        oncurrently, Darzalex is also being evaluated as a potential maintenance treatment for MM. In the Phase III AURIGA trial, the combination of Darzalex plus Revlimid (lenalidomide) versus Revlimid alone is being studied as maintenance treatment in approximately 214 patients with newly diagnosed MM who are MRD positive following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #116

                                          The primary outcome measure is percentage of patients achieving MRD-negative status with results anticipated next year.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper